BIOSITE AND OXFORD GENOME SCIENCES ENTER INTO COLORECTAL CANCER AGREEMENT

A A

UK-based Oxford Genome Sciences has announced a collaboration with California's Biosite for the evaluation of protein-based disease markers for colorectal cancer. These markers, say the companies, could be used for the development of potential blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer.

In particular, the blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option.

"We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies," said Kim Blickenstaff, Biosite's chairman and CEO. "This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers."